A drug utilization study of thiocolchicoside‐containing medicinal products for systemic use in France and Italy: A cross‐sectional electronic medical records database study

Purpose The risk minimization measures (RMM) for systemic use of thiocolchicoside (TCC) was implemented across Europe during 2014–2016. RMM included restriction of use in age 95% and >80%, respectively), while IGP prescribing intramuscular formulation (>70%). Prescriptions to patients aged ≥16...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiology and drug safety 2023-10, Vol.32 (10), p.1093-1102
Main Authors: Druet‐Cabanac, Annie, Sophie, Jouaville Laurence, Afshari, Reza, Sahnoun, Rachid, Kouao‐Kanga, Germain, Toussi, Massoud, Granados, Denis
Format: Article
Language:English
Subjects:
Birth control
Chronic illnesses
Contraception
drug utilization study
Electronic medical records
Lactation
Medical records
prescription
risk minimization measures
safety
thiocolchicoside
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The risk minimization measures (RMM) for systemic use of thiocolchicoside (TCC) was implemented across Europe during 2014–2016. RMM included restriction of use in age 95% and >80%, respectively), while IGP prescribing intramuscular formulation (>70%). Prescriptions to patients aged ≥16 years were >99% in all panels during both periods. An improvement was observed in compliance with treatment duration for oral formulation in the FGP panel post‐implementation versus pre‐implementation (66.2% vs. 46.7%; p 
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.5611